FDA Approves Bayer/J&J's Xarelto for Stroke Prevention

The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm (non-valvular atrial fibrillation). Read more here.